QQQ   415.52 (+0.21%)
AAPL   165.61 (+0.37%)
MSFT   398.78 (-0.09%)
META   479.68 (-0.29%)
GOOGL   155.21 (+0.73%)
AMZN   175.49 (+0.49%)
TSLA   140.78 (-4.26%)
NVDA   779.59 (+2.31%)
AMD   147.61 (+0.66%)
NIO   3.87 (+1.84%)
BABA   70.14 (+1.55%)
T   16.29 (-1.33%)
F   12.62 (+3.95%)
MU   107.82 (+0.98%)
GE   149.74 (+1.13%)
CGC   7.72 (-2.65%)
DIS   112.08 (-0.47%)
AMC   3.39 (+7.28%)
PFE   26.37 (+1.42%)
PYPL   62.73 (+0.67%)
XOM   120.59 (+0.59%)
QQQ   415.52 (+0.21%)
AAPL   165.61 (+0.37%)
MSFT   398.78 (-0.09%)
META   479.68 (-0.29%)
GOOGL   155.21 (+0.73%)
AMZN   175.49 (+0.49%)
TSLA   140.78 (-4.26%)
NVDA   779.59 (+2.31%)
AMD   147.61 (+0.66%)
NIO   3.87 (+1.84%)
BABA   70.14 (+1.55%)
T   16.29 (-1.33%)
F   12.62 (+3.95%)
MU   107.82 (+0.98%)
GE   149.74 (+1.13%)
CGC   7.72 (-2.65%)
DIS   112.08 (-0.47%)
AMC   3.39 (+7.28%)
PFE   26.37 (+1.42%)
PYPL   62.73 (+0.67%)
XOM   120.59 (+0.59%)
QQQ   415.52 (+0.21%)
AAPL   165.61 (+0.37%)
MSFT   398.78 (-0.09%)
META   479.68 (-0.29%)
GOOGL   155.21 (+0.73%)
AMZN   175.49 (+0.49%)
TSLA   140.78 (-4.26%)
NVDA   779.59 (+2.31%)
AMD   147.61 (+0.66%)
NIO   3.87 (+1.84%)
BABA   70.14 (+1.55%)
T   16.29 (-1.33%)
F   12.62 (+3.95%)
MU   107.82 (+0.98%)
GE   149.74 (+1.13%)
CGC   7.72 (-2.65%)
DIS   112.08 (-0.47%)
AMC   3.39 (+7.28%)
PFE   26.37 (+1.42%)
PYPL   62.73 (+0.67%)
XOM   120.59 (+0.59%)
QQQ   415.52 (+0.21%)
AAPL   165.61 (+0.37%)
MSFT   398.78 (-0.09%)
META   479.68 (-0.29%)
GOOGL   155.21 (+0.73%)
AMZN   175.49 (+0.49%)
TSLA   140.78 (-4.26%)
NVDA   779.59 (+2.31%)
AMD   147.61 (+0.66%)
NIO   3.87 (+1.84%)
BABA   70.14 (+1.55%)
T   16.29 (-1.33%)
F   12.62 (+3.95%)
MU   107.82 (+0.98%)
GE   149.74 (+1.13%)
CGC   7.72 (-2.65%)
DIS   112.08 (-0.47%)
AMC   3.39 (+7.28%)
PFE   26.37 (+1.42%)
PYPL   62.73 (+0.67%)
XOM   120.59 (+0.59%)
NASDAQ:VCEL

Vericel (VCEL) Stock Price, News & Analysis

$44.31
+0.57 (+1.30%)
(As of 11:43 AM ET)
Today's Range
$43.88
$44.69
50-Day Range
$43.74
$52.90
52-Week Range
$29.24
$53.05
Volume
48,592 shs
Average Volume
548,345 shs
Market Capitalization
$2.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.40

Vericel MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6.1% Upside
$46.40 Price Target
Short Interest
Bearish
9.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Vericel in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$2.90 M Sold Last Quarter
Proj. Earnings Growth
455.56%
From $0.09 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.58 out of 5 stars

Medical Sector

855th out of 907 stocks

Biological Products, Except Diagnostic Industry

149th out of 154 stocks

VCEL stock logo

About Vericel Stock (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

VCEL Stock Price History

VCEL Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Vericel Corp
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Analyst Scoreboard: 5 Ratings For Vericel
VCEL Oct 2024 50.000 call
A Closer Look at 4 Analyst Recommendations For Vericel
Vericel Corporation (VCEL)
CRSP Mar 2024 79.000 put
See More Headlines
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/22/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VCEL
Employees
314
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$46.40
High Stock Price Target
$54.00
Low Stock Price Target
$39.00
Potential Upside/Downside
+4.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-3,180,000.00
Pretax Margin
-1.20%

Debt

Sales & Book Value

Annual Sales
$197.52 million
Cash Flow
$0.02 per share
Book Value
$4.73 per share

Miscellaneous

Free Float
44,897,000
Market Cap
$2.14 billion
Optionable
Optionable
Beta
1.71

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives


VCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Vericel stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings
or view top-rated stocks.

What is Vericel's stock price target for 2024?

6 analysts have issued 1-year price objectives for Vericel's shares. Their VCEL share price targets range from $39.00 to $54.00. On average, they anticipate the company's stock price to reach $46.40 in the next year. This suggests a possible upside of 6.1% from the stock's current price.
View analysts price targets for VCEL
or view top-rated stocks among Wall Street analysts.

How have VCEL shares performed in 2024?

Vericel's stock was trading at $35.61 at the beginning of 2024. Since then, VCEL stock has increased by 22.8% and is now trading at $43.74.
View the best growth stocks for 2024 here
.

Are investors shorting Vericel?

Vericel saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,390,000 shares, an increase of 85.2% from the March 15th total of 2,370,000 shares. Based on an average daily volume of 536,800 shares, the days-to-cover ratio is currently 8.2 days.
View Vericel's Short Interest
.

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our VCEL earnings forecast
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) posted its quarterly earnings data on Thursday, February, 29th. The biotechnology company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.08. The biotechnology company had revenue of $65 million for the quarter, compared to analyst estimates of $64.28 million. Vericel had a negative trailing twelve-month return on equity of 1.55% and a negative net margin of 1.61%. The company's revenue was up 23.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.12 EPS.

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $237.0 million-$241.0 million, compared to the consensus revenue estimate of $240.8 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Who are Vericel's major shareholders?

Vericel's stock is owned by a variety of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (1.73%), Allspring Global Investments Holdings LLC (0.82%), Congress Wealth Management LLC DE (0.22%), State of Alaska Department of Revenue (0.06%), Los Angeles Capital Management LLC (0.06%) and Mesirow Financial Investment Management Inc. (0.02%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends
.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VCEL) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners